The Incidence of Endophtalmitis after the Application of Intravitreal Injections in FNKV with Regard to Various Prophylactic Antibiotic Regimens
Authors:
Z. Straňák; M. Veith; P. Studený; M. Penčák
Authors place of work:
Praha, přednosta kliniky
prof. MUDr. Pavel Kuchynka, CSc.
; Oftalmologická klinika, Fakultní
nemocnice Královské Vinohrady
Published in the journal:
Čes. a slov. Oftal., 70, 2014, No. 5, p. 184-188
Category:
Original Article
Summary
Aim:
Comparing the incidence of endophtalmitis at the Ophthalmologic clinic of FNKV after the application of intravitreal injections with regard to various prophylactic antibiotic regimens.
Methodics:
Comparing the number of endophtalmitis cases during the period of 2005–2011, when the intravitreal applications were secured by full antibiotic prophylaxis (Floxal)/Oftaquix gtt. 5xd 3 days before the application and 3 days after the application with the years of 2012–2013, when Vigamox gtt. was used during the preparation of the eye before surgery to prevent inflammatory changes.
Results:
In the years of 2005–2013, 5005 injections were applied. In total we recorded three cases of endophthalmitis. In all cases, a pars plana vitrectomy with sample collection for culture and microbiological analysis was performed. During the years of 2005–2011, 2 651 injections were applied with two cases of endophtalmitis (0,075%, 1:1 325, both cases culture-negative). During the years of 2012–2013, 2 355 injections were applied with one case of endophtalmitis (0,042 %, 1:2 355, culture-positive).
Conclusion:
According to our experience, limited prophylactic antibiotic regimen does not increase the incidence of endophtalmitis in comparison with full prophylactic antibiotic regimen.
Key words:
intravitreal injections, antibiotic, endophtalmitis, prophylactic
Zdroje
1. Antoszyk AN, Tuomi L, Chung CY, Singh A.: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 resoluts. Am J Ophthalmol, 2008; 145: 862–874.
2. Artunay O, Yuzbasioglu E, Rasier R, et. al.: Incidence and management of acute endophtalmitis after intravitreal bevazizumab (Avastin) injection. Eye (Lond), 2009; 23: 2187–2193.
3. Bhatt SS, Stepien KE, Joshi K.: Prophylactic antibiotic use after intravitreal injections: effect on endophtalmitis rate. Retina, 2011; 31: 2032–6.
4. Bhavsar AR, Google JM Jr, Stockdale CR, et. al.: Risk of endophtalmitis after intravitreal drug injection hen topical antibiotik ale not required: the diabetic retinophathy clinical resech network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol, 2009; 127: 1581–1583.
5. Bhavsar AR, Ip MS, Glassman AR, et al.: DRCRnet and the SCOREStudy Groups. The risk of endophtalmitis following intravitreal triamcinolone injections in the DRCRnet and SCORE clinical trials. Am J Ophthalmol, 2007; 144: 454–6.
6. Brown DM, Kaiser PK, Michels M, et. al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med ,2006; 355:1 432–1444.
7. Brown DM, Michels M, Kaider PK, et al.: ANCHOR Study group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology, 2009; 116: 57–65.
8. Diago T, McCannl CA, Bakri SJ, et. al.: Infectious endophtalmitic after intravitreal injection of antiangiogenetic agents. Retina, 2009; 29: 601–605.
9. Fintak DR, Shan GK, Blinder KJ et. al.: Incidence of endophtalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina, 2008; 28: 1395–1399.
10. Friedman DA, Mason JO, Emond T, McGwin G Jr., Providone-iodine contact time and lid speculum use during intravitreal injection. Retina, 2013 May; 33(5): 975–81.
11. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004; 351: 2805–2816.
12. Heier JS, Antoszyk AN, Pavan PR, et al.: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled multidose study. Ophthalmology 2012; 113: 633–642.
13. Holland EJ, Lane S, Kim T, et al.: Human cornea and aqueous humor concentration of moxifloxacin and gatifloxacin following topical ocular dosing with Vigamox solution or Zimar. Invest Ophthalmol Vis Sci, 2006; 47: E-Abstract 3577.
14. Chen E LM, Cox J, Brown DM.: Meta-analysis of endoftalmitis after intravitreal injections of anti-VEGF agents: causative organism and possible preventiv strategies. Paper presented at: American Society of Retina Specialist Annual Meeting, September 1, 2010, Vancouver, Canada.
15. Cheung CS, Wong AW, Lui A, et. al.: Incidence of endophtalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology, 2012; 119: 1609–1614.
16. Kim DH, Stark WJ, OęBraien TP, et al.: Ocular penetration od moxifloxacine 0,5% nad gatifloxacin 0,3% ophthalmic solutions into the aqueous humor following topical administration prior to rutine cataract. Curr Med Res Opin. 2005:21(1):93-94. kim Dh, et al. IOVS 2005”46”ARVO E-Abstract 4890.
17. Klein KS, Walsh MK, Hassan TS, et al. Endophtalmitis after anti-VEGF injections. Ophthalmology, 2009; 116: 1225 el.
18. Kowalski RP, et al.: An ophthalmologistęsguide to understating antibiotic susceptibility and minimum inhibitory concentration data, Ophthalmology, 2005;112: 1987–1991.
19. Lam, Waheeb: World Ophthalmology Congress (WOC) 2012: Abstract FP-RET-FR 122 (8) and FP-RET-FR 122 (4). Presented February 17, 2012.
20. Mason JO III, White MF, Feist RM, et. al.: Incidence of acute onset endophtalmitis following intravitreal bevacizumab (Avasitn) injection. Retina, 2008; 28: 564–567.
21. Mather R, Karenchak LM, Romanowski EG, Kovalski RP.: Fourth generation fluoroquinolones: new weapons in the arsenal of ophtalmic antibiotics. Am J Ophthamol, 2002; 133: 463–466.
22. Michelotti MM, Abugreen S, Kelly SP, Morarji J, Myerscough D, Boddie T, Haughton A, Nixon N, Mason B, Sioras E.: Transformational change: nurses substituting for ophthalmologists for intravitreal injections – a quality-improvement report. Clin Ophthalmol, 2014 Apr 15; 8: 755–61.
23. Milder E, Vander J, Shah C, Garg S.: Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology, 2012 Jul; 119(7): 1420–4.
24. Moshfeghi AA, Rosenfeld PJ, Flynn HW, Jr, et. al.: Endophtalmitis after intravitreal anti-vascular endothelial growth factor antagonist: a six-year experience at a university referral center. Retina 2011; 31: 662–668.
25. Moss JM, Sanislo SR, Ta CN.: A prospective randomized evaluation of topical gatifloxacin on conjuctival flora in patiens undergoing intravitreal injections. Ophthalmology, 2009; 116: 1498–501.
26. Pilli S, Kotsolis A, Spaide RF, et. al.: Endophtalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol, 2008;145: 879–882.
27. Rosenfeld PJ, Brown DM, Heier JS, et al.: ANCHOR Study Group. Ranibizumab for neovaskular age-related macular degeneration. N Engl J Med, 2006; 355: 1419–31.
28. Rosenfeld PJ, Brown DM, Heier JS, et. al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006; 355: 1419–1431.
29. Shah CP, Garg SJ, Vander JF, et al.: Post-Injection Endophtalmitis (PIE) Study Team. Outcomes and risk factors associated with endophtalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology, 2011; 118: 2028–34.
30. Shan CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophtalmitis after intravitreal injections of anti-vascular endothelial growth factor agent. Ophthalmology, 2011; 118: 2028–2034.
31. Speaker MG, Menikoff JA.: Prophylaxis of Endoftalmitis with topical providine-iodine. Ophthalmology, 1991; 98: 1769–75.
32. Steinle NC, Chappelow AV, Singh RP.: Avoidance of Endophtalmitis after Intravitreal Injections. Retinal Physician, 2009.
33. Storey P., Dollin M., Pitcher J, et al.: The Role of Topical Antibiotic Prophylaxis to Prevent Endophthalmitis after Intravitreal Injection. Ophthalmology, 2014; 121: 283–289.
34. Studnička J., Beránek J., Ryšková L., Rencová E., Hejsek L., Rozsíval P.: Hodnocení bakteriální kolonizace spojivkového vaku pacientů léčených intravitreálními injekcemi ranibizumabu, Čes a slov Oftal, 2012; 68: 51–55.
35. Tabandeh H., Boscia F, Sborgia A, at al.: Endophtalmitis Assocated with Intravitreal Injections. Retina, 2014; 34: 18–23.
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2014 Číslo 5
Najčítanejšie v tomto čísle
- Oculars Disturbances as First Sign of Decompensated Arterial Hypertension
- Retinal Tamponade with Silicone Oil – Long Term Results
- The Glaucoma Pharmacological Treatment and Biomechanical Properties of the Cornea
- The Incidence of Endophtalmitis after the Application of Intravitreal Injections in FNKV with Regard to Various Prophylactic Antibiotic Regimens